文献速递胸部肿瘤放疗姑息放疗与转移瘤

立体定向体部放疗用于颅外寡进展或寡复发小细胞肺癌

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-05-03

四中心回顾性分析20例颅外寡进展/寡复发小细胞肺癌患者共24个病灶接受SBRT,中位随访2.9年局部无复发,15/20例出现远处复发,中位远处复发4.5个月、中位总生存17.2个月,初诊局限期是唯一与较低远处复发风险相关的因素,无严重SBRT相关毒性。

要点

  • 20例寡进展/寡复发小细胞肺癌患者接受SBRT,中位随访2.9年局部无复发。
  • 15/20例出现远处复发,中位远处复发4.5个月,中位总生存17.2个月。
  • 初诊局限期(对比广泛期)与较低远处复发风险相关(HR 0.3,95%CI 0-0.88,p=0.03)。

核心结论

  • 预后差,多数患者出现远处复发,但局部控制极佳,寡进展/寡复发小细胞肺癌患者SBRT后罕见长期缓解。
  • 作者认为局部消融治疗应在多学科框架下对经过良好选择的病例进行讨论。

研究设计与样本

  • 四中心回顾性分析,纳入接受SBRT治疗寡进展/寡复发转移性疾病的SCLC患者20例,共24个病灶。
  • 排除同步寡转移、针对原发肺部肿瘤的SBRT及脑部放射外科治疗患者。
  • 复发率和生存率定义为SBRT日期至首次事件的时间。

主要发现

  • 20例中初诊局限期占60%,寡进展6/20(30%),寡复发14/20(70%)。
  • SBRT照射1个病灶16例、2个病灶4例,中位病灶大小26 mm,主要照射肺转移灶(17/24)。
  • 中位随访2.9年,无局部复发,15/20例出现远处复发。
  • 中位远处复发4.5个月(95%CI 2.9-13.7个月),中位总生存17.2个月(95%CI 7.5-65.2个月)。
  • 3年远处控制率25%(95%CI 6-44%),3年总生存率37%(95%CI 15-59%)。

临床怎么用

  • 原文未据此给出推荐,仅作者认为局部消融治疗应在多学科框架下对经过良好选择的病例进行讨论。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The role of local ablative treatments, including stereotactic body radiotherapy (SBRT), is an area of active research in oligometastatic patients. Small cell lung cancer (SCLC) has a poor prognosis, with common diffuse metastatic evolution. We evaluated the outcomes after SBRT in uncommon oligoprogressive/oligorecurrent SCLC presentation. METHODS: Data of SCLC patients who received SBRT for oligoprogressive/oligorecurrent metastatic disease at four centers were retrospectively analyzed. Patients with synchronous oligometastatic disease, SBRT for primary lung tumor and brain radiosurgery were not included. Relapse and survival rates were defined as the time between the date of SBRT and the first event. RESULTS: Twenty patients (60% with initially limited-disease [LD]) presenting 24 lesions were identified. Oligoprogression and oligorecurrence were observed in 6/20 (30%) and 14/20 (70%) patients, respectively. SBRT was delivered to one (n = 16) to two (n = 4) lesions (median size, 26 mm), mainly to lung [n = 17/24] metastases. At a median follow-up of 2.9 years, no local relapse was observed and 15/20 patients experienced a distant relapse (DR). The median DR and OS were 4.5 months (95 %CI: 2.9-13.7 months) and 17.2 months (95 %CI: 7.5-65.2 months), respectively. The 3-year distant control and OS rates were 25% (95 %CI: 6-44%) and 37% (95 %CI: 15-59%), respectively. Initial LD (vs extensive-disease) was the only prognosis factor associated with a lower risk of post-SBRT DR (HR: 0.3; 95% CI: 0-0.88; p = 0.03). There was no severe observed SBRT-related toxicities. CONCLUSION: Prognosis was poor, with DR occurring in most patients. However, local control was excellent and long term response after SBRT may rarely occur in patients with oligoprogressive/oligorecurrent SCLC. Local ablative treatments should be discussed in a multidisciplinary setting on well-selected cases.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Levy A, Khalifa J, Martin E, et al. Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer. Clin Transl Radiat Oncol. 2023. PMID: 37206411. doi:10.1016/j.ctro.2023.100637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。